Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity.
- Published In:
- Diabetes therapy : research, treatment and education of diabetes and related disorders, 16(6), 1207-1227 (2025)
- Authors:
- Volčanšek, Špela, Koceva, Andrijana(2), Jensterle, Mojca(4), Janež, Andrej, Muzurović, Emir
- Database ID:
- RPEP-13944
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13944APA
Volčanšek, Špela; Koceva, Andrijana; Jensterle, Mojca; Janež, Andrej; Muzurović, Emir. (2025). Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity.. Diabetes therapy : research, treatment and education of diabetes and related disorders, 16(6), 1207-1227. https://doi.org/10.1007/s13300-025-01733-8
MLA
Volčanšek, Špela, et al. "Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity.." Diabetes therapy : research, 2025. https://doi.org/10.1007/s13300-025-01733-8
RethinkPeptides
RethinkPeptides Research Database. "Amylin: From Mode of Action to Future Clinical Potential in ..." RPEP-13944. Retrieved from https://rethinkpeptides.com/research/volcansek-2025-amylin-from-mode-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.